ANI Pharma Q3 2022: Record revenue $83.8M (+61% YoY); GAAP loss $(9.0M); adj. EPS $0.64; Cortrophin $12.6M

ANI PHARMACEUTICALS INC

2022-Q3 EPS reported -$2.76 revenue$222,153,000

Record net revenues of $83.8M, up 61% YoY from $52.1M.
GAAP net loss $(9.0M) and diluted loss per share $(0.55), compared to loss $(4.4M) and $(0.37) in Q3 2021.
Adjusted non-GAAP EBITDA $19.6M (nearly double Q2 2022) and adjusted diluted EPS $0.64, down from $1.01 in Q3 2021.
Cortrophin net sales $12.6M; cumulative patient cases 765+; reiterated full-year Cortrophin revenue guidance $40-45M; full-company guidance also reaffirmed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ANI PHARMACEUTICALS INC reported three and nine months ended September 30, 2022 results: revenue $83.8 million, net income $(9.0) million, EPS $(0.55). Guidance reaffirmed.

Period: three and nine months ended September 30, 2022
Revenue: $83.8 million
Net income: $(9.0) million
EPS: $(0.55)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

ANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net Revenues Third Quarter 2022 Results: -- Net revenues of $83.8 million, net loss available to common shareholders of $(9.0) million and diluted GAAP loss per share of $(0.55)

View on SEC.gov

Browse all earnings releases →

ANI PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-22-116252

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.